CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy.
Adenosine
/ metabolism
Adenosine A2 Receptor Antagonists
/ pharmacology
Animals
CRISPR-Cas Systems
/ genetics
Cell Engineering
/ methods
Cell Line, Tumor
/ transplantation
Disease Models, Animal
Female
Gene Editing
Gene Expression Regulation, Neoplastic
/ immunology
Gene Knockdown Techniques
Gene Knockout Techniques
Humans
Immunotherapy, Adoptive
/ methods
Lymphocytes, Tumor-Infiltrating
/ immunology
Mice
Mice, Transgenic
Neoplasms
/ genetics
RNA, Small Interfering
/ metabolism
RNA-Seq
Receptor, Adenosine A2A
/ genetics
Receptor, ErbB-2
/ genetics
Receptors, Chimeric Antigen
/ immunology
Signal Transduction
/ drug effects
T-Lymphocytes
/ immunology
Tumor Escape
/ drug effects
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
28 05 2021
28 05 2021
Historique:
received:
09
08
2020
accepted:
22
04
2021
entrez:
29
5
2021
pubmed:
30
5
2021
medline:
9
6
2021
Statut:
epublish
Résumé
Adenosine is an immunosuppressive factor that limits anti-tumor immunity through the suppression of multiple immune subsets including T cells via activation of the adenosine A
Identifiants
pubmed: 34050151
doi: 10.1038/s41467-021-23331-5
pii: 10.1038/s41467-021-23331-5
pmc: PMC8163771
doi:
Substances chimiques
ADORA2A protein, human
0
Adenosine A2 Receptor Antagonists
0
Adora2a protein, mouse
0
RNA, Small Interfering
0
Receptor, Adenosine A2A
0
Receptors, Chimeric Antigen
0
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Adenosine
K72T3FS567
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3236Références
J Clin Invest. 2017 Mar 1;127(3):929-941
pubmed: 28165340
Immunol Lett. 2020 Jul;223:44-52
pubmed: 32289340
Bioinformatics. 2012 Jun 1;28(11):1530-2
pubmed: 22539670
Cancer Immunol Res. 2015 May;3(5):506-17
pubmed: 25672397
Sci Transl Med. 2015 Mar 4;7(277):277ra30
pubmed: 25739764
Br J Haematol. 2014 Jun;165(5):722-5
pubmed: 24666252
Blood. 1997 Aug 15;90(4):1600-10
pubmed: 9269779
Clin Transl Immunology. 2019 May 05;8(5):e1046
pubmed: 31073403
Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19051-6
pubmed: 16365285
Science. 2020 Feb 28;367(6481):
pubmed: 32029687
J Clin Invest. 2018 Nov 1;128(11):5137-5149
pubmed: 30188869
Mol Ther. 2013 Nov;21(11):2122-9
pubmed: 23831595
Cancer Res. 2014 Dec 15;74(24):7239-49
pubmed: 25341542
Mol Med. 2016 Dec;22:694-704
pubmed: 27761584
Cancer Immunol Res. 2019 Feb;7(2):183-192
pubmed: 30651288
Trends Immunol. 2012 May;33(5):231-7
pubmed: 22487321
Nucleic Acids Res. 2012 May;40(10):4288-97
pubmed: 22287627
Nat Commun. 2019 Apr 10;10(1):1668
pubmed: 30971695
Nat Cancer. 2020 Mar;1(3):291-301
pubmed: 32566933
Cancer Immunol Res. 2018 Oct;6(10):1136-1149
pubmed: 30131376
J Biol Chem. 2010 Dec 10;285(50):39271-88
pubmed: 20926384
EMBO J. 2020 Jan 15;39(2):e103637
pubmed: 31803974
Bioinformatics. 2011 Jun 15;27(12):1739-40
pubmed: 21546393
Cancer Res. 2017 Mar 15;77(6):1296-1309
pubmed: 28082401
Cancer Immunol Res. 2014 Jul;2(7):598-605
pubmed: 24990240
Mol Ther Nucleic Acids. 2014 Dec 02;3:e214
pubmed: 25462530
Cancer Immunol Immunother. 2018 Aug;67(8):1271-1284
pubmed: 29923026
Oncoimmunology. 2016 Jan 19;5(5):e1127496
pubmed: 27467942
Cytotherapy. 2020 Feb;22(2):57-69
pubmed: 32014447
Cancer Gene Ther. 2016 May;23(5):142-8
pubmed: 27080226
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
J Biol Chem. 1997 Oct 10;272(41):25881-9
pubmed: 9325320
Nat Immunol. 2020 Aug;21(8):914-926
pubmed: 32424363
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
JCI Insight. 2020 Feb 27;5(4):
pubmed: 31999649
Cancer Res. 2010 Dec 1;70(23):9591-8
pubmed: 21098715
Nature. 2001 Dec 20-27;414(6866):916-20
pubmed: 11780065
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):11091-6
pubmed: 23776241
Clin Cancer Res. 2013 Oct 15;19(20):5636-46
pubmed: 23873688
Cancer Immunol Immunother. 2012 Jun;61(6):917-26
pubmed: 22116345
Tumour Biol. 2015 Dec;36(12):9411-9
pubmed: 26113408
Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13132-7
pubmed: 16916931
Science. 2020 Sep 18;369(6510):1481-1489
pubmed: 32792462
Nat Med. 2018 May;24(5):563-571
pubmed: 29713085
Cancer Res. 2014 Dec 1;74(23):6796-805
pubmed: 25297631
J Clin Invest. 2020 Nov 2;130(11):5629-5637
pubmed: 32870821
Cancer Discov. 2020 Jan;10(1):16-19
pubmed: 31919119
Comput Struct Biotechnol J. 2015 Apr 08;13:265-72
pubmed: 25941561
Int J Mol Sci. 2018 Dec 02;19(12):
pubmed: 30513816
Nat Med. 2019 Jan;25(1):82-88
pubmed: 30559421
Nucleic Acids Res. 2018 Jan 4;46(D1):D754-D761
pubmed: 29155950
Sci Rep. 2017 Apr 7;7(1):737
pubmed: 28389661
BMC Cancer. 2018 Mar 7;18(1):267
pubmed: 29514610
Biochem Pharmacol. 2003 Jun 15;65(12):2081-90
pubmed: 12787889
Front Immunol. 2019 Jun 06;10:925
pubmed: 31244820
Cancer Res. 2015 Nov 1;75(21):4494-503
pubmed: 26363007
Cancer Res. 2010 Mar 15;70(6):2245-55
pubmed: 20179192
Oncol Lett. 2015 Jun;9(6):2485-2494
pubmed: 26137095
Nat Med. 2020 May;26(5):732-740
pubmed: 32341578
Nucleic Acids Res. 2000 Jan 1;28(1):27-30
pubmed: 10592173
J Immunol. 2004 Jul 1;173(1):21-4
pubmed: 15210754
Nat Cancer. 2020 Mar;1(3):302-314
pubmed: 32803171
J Immunol. 2001 Jan 1;166(1):182-7
pubmed: 11123291
J Immunol. 2004 Aug 1;173(3):2143-50
pubmed: 15265951
Mol Ther. 2020 Nov 4;28(11):2379-2393
pubmed: 32735774
J Exp Clin Cancer Res. 2020 Mar 10;39(1):49
pubmed: 32151275
J Immunol. 2020 Apr 15;204(8):2308-2315
pubmed: 32152070
J Immunol. 2018 Jul 15;201(2):782-791
pubmed: 29802128
Sci Transl Med. 2019 Jun 5;11(495):
pubmed: 31167925
PLoS Biol. 2017 Nov 30;15(11):e2003213
pubmed: 29190685
Oncoimmunology. 2018 Apr 18;7(8):e1452579
pubmed: 30221045